SDA-A-1

........10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250.......260.......270.......280.......290.......300.......310.......320.......330.......340.......350......... MHPSTS---RPSRRTLLTATAGAA---LAAAT--LVPGT--AHA--SSGGRGHGSGSVSDAERRLAGLERASGARLGVYAYDTGSGRTVAYRADELFPMCSVFKTLSSAAVLRDLDRNGEFLS---------RRILYTQDDVEQADGAGPETGKPQNLANAQLTVEELCEVSITASDNCAANLMLRELGGPAAVTRFVRSLGDRVTRLDRWEPELNSAEPGRVTDTTSPRAITRTYGRLVLGD----ALNPRDRRLLTSWLLANTTSGDRFRAGLPDDWTLGDKTGAG-RYGTNNDAGVTWPPGRAPIVLTVLTAKT-EQDAARDDGLVADAARVLAETLG------------------

SDA-D-1	------MRI..T..L..G.V.PL.LVP.V.CGQ--AS.SESGQQPGLG.CGTSAH..ADAH.KEFRA..KKFD.HP....I..RD.QEITH....R.AYG.T..A.QAG.I.AQVL.D.REVRRGAEADGMDKVVH.G..A------IL.NSPVTEKHVADGMSLR...DAVVAY...T....LFDQ...RRGS..VLKQ...HT.SM..Y.Q..G..V..DPR..ST...FAEDLRAFAVE.GEKA..A.N..EQ.ND.MSGSR.GDALI...V.K..KVE..S.QV-K...R..IA.VR........VS.MSHGD-T...EPH.E...E.GL.V.DG.K------------------	35.50 %
SDA-D-2	------MRI..T..L..G.V.PL.LVP.V.CGQ--AS.SES.GSSPA.AV.TSAH..ADAH.KEFRA..KKFD.T.....I..AD.QEITH....R.AYG.T..A.QAG.I..KFSET.AKSGGGAEADGMDKVVH.G..A------IL.NSPVTEKHVADGMSLR...DAVVRY...T....LFDQ....KGLNAVLKQ...HT.SM..Y.Q..G..V..DPR..ST...FAEDLRAFAVE.GEKA..A.N..EQ.ND.MSG.A.GDALI...V.K..KVA..S.QV-K...R..IA.VR........VS.MSHGD-T...EPH.E...E..S.V.DG.K------------------	36.69 %
SDA-D-3	------MRI..T..L..G.V.PL.LVP.V.CGQ--AS.SES.GSSPA.AV.TSAH..ADAH.KEFRA..KKFD.T.....I..AD.QEITH....R.AYG.T..A.QAG.I..KFSET.AKSGAGAEADGMDKVVH.G..A------IL.NSPVTEKHVADGMSLR...DAVVRY...T....LFDQ....KGLNAVLKQ...HT.SM..Y.Q..G..V..DPR..ST...FAEDLRAFAVE.GKKA..A.N..EQ.ND.MSG.A.GDALI...V.K..KVA..S.QV-K...R..IA.VR........VS.MSHGD-TE..EPH.E...E..S.V.DG.K------------------	36.39 %
SDA-E-1	.RKP..---SLT..SV.G.GL.LG---G.-----.AL.S--TT.--.AASA.TTPSENPA.V...RA...EHQ..I..F.LNLAT.ASLLH..H............AA........HD.SQ.A---------.V.R..EA..T-KS.HA.V.K---DHIDTGM.IRD..DAT.RY........L.......T.....C.....P.............G..D.R......Y..A...Q.....N----...RP..A...D...R...TLTT..T...KG..VA..S.G.DT...R.E.AIA.T.DG..VL..A..H.PSLPT.PG.TP.IIKL.T..S.AVAPA----------------	52.52 %
SDA-F-1	.DRT.A---..N..AV.ATGV...---...TA--AAA.P--...--AP.RG-------ARV.G..RA...THD....AF.....T..........R..IA.M...IAV.........D..V.A---------..VH..A.Y.K-RS.YS.V..L.E.V..-GM..A....ATL.R...T....L..D....T.....C..V..H............................G......I...----L.AAH..ER..R.M.D.R..DE...K...A..L.A....G.-D.........A.....P.V..A.Q.TRF-TP..EA.NV...E...L...AMTD-----------------	62.22 %
SDA-F-2	.DRT.A---..N..AV.ATGV...---...TA--AAA.P--...--AP.RG-------ARV.G..RA...THD....AF.....T..........R..IA.M...IAV.........D..V.A---------..VH..A.Y.K-RS.YS.V..L.E.V..-GM..A....ATL.R...T....L.HD....T.....C..V..H............................G......I...----L.AAH..ER..R.M.D.R..DE...K...A..L.A....G.-D.........A.....P.V..A.Q.TRF-TP..EA.NV...E...L...AMTD-----------------	61.90 %
SDA-G-1	.RAGAVRPSAV...A....A.LLP---..GCGTRERT.SPP.SV--RAA...SPGAEGRARVAD..A...EH........LE..T.AE..H....R.AF..T..A.AA....HHH--PIRH.E---------..VTW.RA..DS------ISPVTEDHIATG...GQ..DAA.RH..GT.G..LM.D....SRL.AYL.G...S.S.M.QY.....HDP.HDPR...T....ASD.RK.....----..T.DR.A...D..VR...G.R.I...V.SG.RVA....T.-N..RA..IA.L...RSS.L.VA.MSDRPGFRTPPSERLIAE.RGAIV.GLVRHPPTHASGAGAPSRHPGP	39.41 %
SDA-L-1	.GTTGA---.....AV...A....---V.GIP--.GGS.--.F.--APR.N-------P.VL.Q.RA..QEHS.......R..AT....LH..E.R..........AV.........D....A---------T.LF..EQE.K-DS.F..V..L.E...A-GM...R..AAA.CQ...A....L.......E.....C..V...T.................L....T....GA...E.....----..A....ER..G........TE...K...A.........G.-A.............H.P.V.MV...THD-RP..VA.NP...KT.AL..SA..------------------	64.01 %

Last updated: November 20, 2024.

If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.

The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).

Contact: contact@bldb.eu

Live statistics (since December 3rd, 2023)